Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Articles
Articles
Dalpiciclib and Pyrotinib in HER2-Positive Advanced BC: Phase 2 DAP-HER-01
ASCO 2023 - Breast Cancer
Updated results of the DAP-HER-01 trial continue to show promising efficacy and manageable toxicity with the oral chemotherapy-free dalpiciclib plus pyrotinib in patients with HER2-positive advanced breast cancer, including the difficult-to-treat subgroups of hormone receptor–negative disease or brain metastases.
Read More ›
Neratinib Plus T-DM1 for HER2-Positive BC With Molecular Residual Disease
ASCO 2023 - Breast Cancer
The phase 2 KAN-HER2 MRD trial will evaluate the addition of neratinib to standard trastuzumab emtansine in patients with HER2-positive breast cancer and evidence of molecular residual disease.
Read More ›
HER2 REAL: Real-World Treatment Patterns in HER2-Positive Unresectable LA/MBC
ASCO 2023 - Breast Cancer
Interim results from the Asia cohort of the HER2 REAL study found heterogeneous treatment patterns among patients with HER2-positive unresectable locally advanced or metastatic breast cancer progressing on HER2-directed therapies.
Read More ›
Tucatinib Plus Trastuzumab Plus Capecitabine Is Efficacious After Trastuzumab Deruxtecan Exposure in HER2-Positive MBC
ASCO 2023 - Breast Cancer
Results of a large multicenter retrospective study confirmed that tucatinib in combination with trastuzumab and capecitabine was efficacious in patients with HER2-positive metastatic breast cancer with previous exposure to trastuzumab deruxtecan.
Read More ›
PERMEATE: Updated Results of Pyrotinib Plus Capecitabine in Patients With HER2-Positive MBC and Brain Metastases
ASCO 2023 - Breast Cancer
Updated results of the phase 2 PERMEATE trial confirmed that pyrotinib plus capecitabine provided long-term survival benefit in patients with HER2-positive metastatic breast cancer and brain metastases.
Read More ›
HER2CLIMB-05: Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for HER2-Positive LA/MBC
ASCO 2023 - Breast Cancer
The phase 3 HER2CLIMB-05 trial is evaluating tucatinib plus trastuzumab and pertuzumab as maintenance therapy in patients with HER2-positive locally advanced or metastatic breast cancer.
Read More ›
PRECIOUS: Pertuzumab Re-treatment Improved OS in HER2-Positive LA/MBC in a Phase 3 Trial, but Did Treatment Imbalances Impact the Outcomes?
ASCO 2023 - Breast Cancer
Updated results of the phase 3 randomized PRECIOUS trial demonstrated that dual HER2 blockade with pertuzumab re-treatment in combination with trastuzumab plus chemotherapy led to significant overall survival improvement compared with trastuzumab plus chemotherapy in patients previously treated with pertuzumab-containing regimens for HER2-positive locally advanced/metastatic breast cancer, but potential imbalances in chemotherapy during and after the study treatment period may have impacted the results.
Read More ›
Wrap-Up
Emerging Treatment Landscape for Multiple Myeloma
ONS 2023 - Multiple Myeloma: Wrap-Up
New targets and innovative therapies for multiple myeloma were highlighted in two sessions presented at ONS 2023.
Read More ›
Wrap-Up
Nursing Considerations for Select Multiple Myeloma Treatments
ONS 2023 - Multiple Myeloma: Wrap-Up
Specific factors to be considered are outlined for the management of multiple myeloma treated with certain therapies.
Read More ›
Wrap-Up
Adverse Event Management in Multiple Myeloma
ONS 2023 - Multiple Myeloma: Wrap-Up
Common treatment-related adverse events and management approaches to multiple myeloma were outlined in three separate sessions at the ONS 2023 Congress.
Read More ›
Page 7 of 136
4
5
6
7
8
9
10
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us